BioNTech SE (BNTX) is a Biotechnology company in the Healthcare sector, currently trading at $98.41. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BNTX = $106.49 (+8.2% from the current price, the stock appears fairly valued). Analyst consensus target is BNTX = $137 (+39.6% upside).
Valuation: BNTX trades at a trailing Price-to-Earnings (P/E) of -16.9 (S&P 500 average ~25).
Financials: revenue is $2.8B, -35.2%/yr average growth. Net income is $1.1B (loss), growing at -108.6%/yr. Net profit margin is -39.6% (negative). Gross margin is 77.6% (-5.1 pp trend).
Balance sheet: total debt is $267M against $19.2B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 7.54 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $22.0B.
Analyst outlook: 20 / 24 analysts rate BNTX as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 15/100 (Fail), Past 50/100 (Partial), Health 67/100 (Partial), Moat 65/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
